;
Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of : Financial News

 Current Issue
  • FINANCIAL NEWS: Foamix trades up after $40.2M IPO

    Israeli dermatology play Foamix Ltd. (NASDAQ:FOMX) was up $0.22 to $6.22 in its first day of trading Thursday after raising $40.2 million through the sale of 6.7 million shares at $6 in an IPO on NASDAQ. The price …

    Published on 9/18/2014
  • FINANCIAL NEWS: OSE Pharma plans IPO on Euronext Paris

    Orphan Synergy Europe-Pharma S.A. plans an IPO on Euronext Paris by year end to fund clinical trials of its immunotherapy Texopi.Texopi is a combination of 10 epitopes targeting five tumor-associated antigens often …

    Published on 9/18/2014
  • FINANCIAL NEWS: Proteon files for IPO

    Proteon Therapeutics Inc. (Waltham, Mass.) filed to raise up to $69 million in an IPO on NASDAQ underwritten by Stifel; JMP Securities; Baird; and Oppenheimer.In August, Proteon began Phase III testing of PRT-201 …

    Published on 9/16/2014
  • FINANCIAL NEWS: Ribomic raises $25.7M in Japanese IPO

    Ribomic Inc. (Tokyo:4591) raised Y2.8 billion ($25.7 million) through the sale of 1.2 million shares at Y2,300 in an IPO on the Tokyo Stock Exchange's Mothers. The price values the company at Y27.8 billion ($258.3 …

    Published on 9/16/2014
  • FINANCIAL NEWS: University of California planning venture fund

    The University of California board of regents is set to vote on Thursday on a proposal to create an independent venture firm with up to $250 million to invest in commercial opportunities that emerge from UC system …

    Published on 9/16/2014
  • FINANCIAL NEWS: Civitas, Eyegate set IPO terms

    Civitas Therapeutics Inc. (Chelsea, Mass.) and EyeGate Pharmaceuticals Inc. (Waltham, Mass.) each set terms for their proposed IPOs on NASDAQ.Civitas plans to sell 5 million shares at $14-$16. At $15, Civitas would …

    Published on 9/15/2014
  • FINANCIAL NEWS: NeuroDerm files for IPO

    NeuroDerm Ltd. (Rehovot, Israel) filed to raise up to $65 million in an IPO on NASDAQ underwritten by Jefferies; Cowen; Oppenheimer; and Roth Capital Partners.NeuroDerm's lead program is ND0612L, a low-dose liquid …

    Published on 9/15/2014
  • FINANCIAL NEWS: Scholar Rock raises $20M series A

    Scholar Rock LLC (Cambridge, Mass.) raised $20 million in a series A round led by new investor Arch Venture Partners. Founding investors Polaris Partners and Timothy Springer joined new investors EcoR1 Capital and The …

    Published on 9/15/2014
  • FINANCIAL NEWS: Affimed raises $56M in IPO

    Affimed Therapeutics B.V. (NASDAQ:AFMD) was down $1.30 to $5.70 on its first day of trading Friday after raising $56 million through the sale of 8 million shares at $7 in an IPO. The IPO price values the company at $167…

    Published on 9/12/2014
  • FINANCIAL NEWS: AM-Pharma raises EUR 12.2M

    AM-Pharma B.V. (Bunnik, The Netherlands) raised EUR 12.2 million ($15.8 million) in a tranched series E round led by Gilde Healthcare.Existing investors participating in the new round included the venture arm of AbbVie…

    Published on 9/12/2014
  • FINANCIAL NEWS: Cancer play Kolltan files for IPO

    Kolltan Pharmaceuticals Inc. (New Haven, Conn.) filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by Leerink Partners; Stifel; Guggenheim Securities; and Janney Montgomery Scott.Kolltan's KTN3379 is in…

    Published on 9/12/2014
  • FINANCIAL NEWS: Polar Capital raising large cap biotech fund

    Polar Capital is fundraising for an open-ended global biotech fund focused on large cap companies. The Polar Capital Healthcare Blue Chip Fund will be managed by Gareth Powell and Daniel Mahony, who have both been with …

    Published on 9/12/2014
  • FINANCIAL NEWS: Virobay files for IPO

    Virobay Inc. (Menlo Park, Calif.) filed to raise up to $50 million in an IPO on NASDAQ underwritten by Piper Jaffray; JMP Securities; Cantor Fitzgerald; and Summer Street Research Partners.Virobay has completed Phase I …

    Published on 9/11/2014
  • FINANCIAL NEWS: Xenon files for IPO

    Xenon Pharmaceuticals Inc. (Burnaby, B.C.) filed to raise up to $51.8 million in an IPO on NASDAQ underwritten by Jefferies and Wells Fargo Securities. Xenon uses its Extreme Genetics platform to discover and develop …

    Published on 9/10/2014
  • FINANCIAL NEWS: Aerie planning $125M note deal

    Aerie Pharmaceuticals Inc. (NASDAQ:AERI) proposed Tuesday to raise $125 million through the sale of senior secured convertible notes to Deerfield Management Company L.P. The notes bear 1.75% interest, mature in …

    Published on 9/9/2014
  • FINANCIAL NEWS: OrbiMed closes new Asia fund with $325M

    OrbiMed Advisors closed its second Asia fund with $325 million, above the firm's $300 million target. According to OrbiMed general partner Carter Neild, OrbiMed will invest OrbiMed Asia Partners II L.P. in 15 to 20 "…

    Published on 9/9/2014
  • FINANCIAL NEWS: Newco Flex raises $40 million in venture round

    Flex Pharma Inc. (Boston, Mass.) raised $40 million in an undisclosed venture round to develop treatments for neuromuscular disorders. Investors include Longwood Fund; Bessemer Venture Partners; EcoR1 Capital; Jennison …

    Published on 9/8/2014
  • FINANCIAL NEWS: PRA Health files for $375 million IPO

    CRO PRA Health Sciences Inc. (Raleigh, N.C.) filed to raise up to $375 million in an IPO on NASDAQ underwritten by Jefferies; Citigroup; KKR; UBS Investment Bank; Credit Suisse; Wells Fargo Securities; Baird; and …

    Published on 9/8/2014
  • FINANCIAL NEWS: ProQR sets IPO range

    ProQR Therapeutics B.V. (Leiden, the Netherlands) set terms for its IPO on NASDAQ. The company plans to sell 6.3 million shares at $11-$13. At the $12 midpoint, the company would raise $75 million and be valued at $251.…

    Published on 9/8/2014
  • FINANCIAL NEWS: Ribomic sets IPO range

    Ribomic Inc. (Tokyo, Japan) plans to sell 1.2 million shares at Y2,000-Y2,300 in its IPO on the Tokyo Stock Exchange's Mothers. At the Y2,150 midpoint Ribomic would raise Y2.6 billion ($24.5 million) and be valued at …

    Published on 9/8/2014
  • FINANCIAL NEWS: Vitae sets IPO terms

    Vitae Pharmaceuticals Inc. (Fort Washington, Pa.) set the terms for its IPO on NASDAQ. The company plans to sell 5 million shares at $11-$13. At the $12 midpoint, Vitae would raise $60 million and be valued at $186 …

    Published on 9/8/2014
  • FINANCIAL NEWS: Clovis prices $250M note deal

    Clovis Oncology Inc. (NASDAQ:CLVS) raised $250 million through the sale of convertible senior notes to institutional investors. The notes bear 2.5% interest and mature on September 15, 2021. The notes initially convert …

    Published on 9/4/2014
  • FINANCIAL NEWS: Depomed raises $300M in bumped-up note deal

    Depomed Inc. (NASDAQ:DEPO) raised $300 million through the sale of convertible senior notes. The notes bear 2.5% interest and mature on Sept. 1, 2021. The notes initially convert at $19.24, a 26% premium to the company'…

    Published on 9/4/2014
  • FINANCIAL NEWS: Fractyl raises $40M in series C

    Diabetes company Fractyl Laboratories Inc. (Waltham, Mass.) raised $40 million in a series C round led by new investor Mithril. Existing investors General Catalyst; Bessemer Venture Partners; and Domain Associates also …

    Published on 9/4/2014
  • FINANCIAL NEWS: Propeller raises $14.5 million in B round

    Propeller Health (Madison, Wis.) raised $14.5 million in a series B round led by new investor Safeguard Scientifics Inc. (NYSE:SFE). Existing investor The Social+Capital Partnership also participated along with …

    Published on 9/4/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993